Estimating the clinical cost of drug development for orphan versus non-orphan drugs

High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool. However, estimates of the cost of orphan drug development are sparse.

Year of Publication: 2019

Authors: Aidan Hollis, Jeffrey S. Hoch, Kavisha Jayasundara, Muhammad Mamdani, Murray Krahn, Paul Grootendorst

Journal Title: Orphanet Journal of Rare Diseases